Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2018

30.10.2017 | Colorectal Cancer

Prognostic Impact of Tumor-Budding Grade in Stages 1–3 Colon Cancer: A Retrospective Cohort Study

verfasst von: Bo Young Oh, MD, PhD, Yoon Ah Park, MD, Jung Wook Huh, MD, PhD, Seong Hyeon Yun, MD, PhD, Hee Cheol Kim, MD, PhD, Ho-Kyung Chun, MD, PhD, Seok Hyung Kim, MD, PhD, Sang Yun Ha, MD, PhD, Woo Yong Lee, MD, PhD, Yong Beom Cho, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Tumor budding is associated with adverse histology and is a predictor of lymph node metastasis. However, it remains unclear whether tumor budding is predictive of a poor prognosis for colon cancer patients. This study sought to investigate the prognostic significance of tumor budding in colon cancer.

Methods

This study evaluated 4196 colon cancer patients who underwent radical surgery from 2007 to 2013 at a single institution. The patients were categorized according to tumor-budding status. Adjustment was made for using propensity score-matched analysis, and both disease-free survival (DFS) and overall survival (OS) were compared between the groups.

Results

Among the 4196 patients, 2269 had low budding (< 5 buds), 1312 had intermediate budding (5–9 buds), and 615 had high budding (≥ 10 buds). High budding was associated with adverse histologic features such as elevated levels of preoperative carcinoembryonic antigen, advanced stage, poor histology, and the presence of lymphatic/vascular/perineural invasion. Before matching, DFS and OS decreased significantly with increasing tumor budding. After matching, the difference in survival between the low- and intermediate-budding groups disappeared. However, the OS and DFS rates for the high-budding group were significantly lower than for the other two groups. In the multivariate analysis of prognostic factors, high budding was an independent poor prognostic factor in DFS and OS, whereas tumor-budding positivity itself was not an independent prognostic factor.

Conclusion

Tumor-budding grade rather than tumor-budding positivity was an independent prognostic factor in colon cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rogers AC, Gibbons D, Hanly AM, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014;27:156–62.CrossRefPubMed Rogers AC, Gibbons D, Hanly AM, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014;27:156–62.CrossRefPubMed
2.
Zurück zum Zitat Imai. The growth of human carcinoma: a morphological analysis. Fukuoka Igaku Zasshi. 1954;45:30. Imai. The growth of human carcinoma: a morphological analysis. Fukuoka Igaku Zasshi. 1954;45:30.
3.
Zurück zum Zitat Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers: lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63:539–43.CrossRefPubMed Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers: lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63:539–43.CrossRefPubMed
4.
Zurück zum Zitat Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 1993;36:627–35.CrossRefPubMed Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 1993;36:627–35.CrossRefPubMed
5.
Zurück zum Zitat Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour “budding” as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127–32.CrossRefPubMed Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour “budding” as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127–32.CrossRefPubMed
6.
Zurück zum Zitat Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum 2006;49:1422–30.CrossRefPubMed Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum 2006;49:1422–30.CrossRefPubMed
7.
Zurück zum Zitat Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299–311.CrossRefPubMed Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299–311.CrossRefPubMed
8.
Zurück zum Zitat Lugli A, Vlajnic T, Giger O, et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol. 2011;42:1833–40.CrossRefPubMed Lugli A, Vlajnic T, Giger O, et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol. 2011;42:1833–40.CrossRefPubMed
9.
Zurück zum Zitat van Wyk HC, Park J, Roxburgh C, Horgan P, Foulis A, McMillan DC. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. Cancer Treat Rev. 2015;41:151–9.CrossRefPubMed van Wyk HC, Park J, Roxburgh C, Horgan P, Foulis A, McMillan DC. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. Cancer Treat Rev. 2015;41:151–9.CrossRefPubMed
10.
Zurück zum Zitat Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer—ready for diagnostic practice? Hum Pathol. 2016;47:4–19.CrossRefPubMed Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer—ready for diagnostic practice? Hum Pathol. 2016;47:4–19.CrossRefPubMed
11.
Zurück zum Zitat Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.PubMed Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.PubMed
12.
Zurück zum Zitat Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33:134–41.CrossRefPubMed Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33:134–41.CrossRefPubMed
13.
Zurück zum Zitat Syk E, Lenander C, Nilsson PJ, Rubio CA, Glimelius B. Tumour budding correlates with local recurrence of rectal cancer. Colorectal Dis. 2011;13:255–62.CrossRefPubMed Syk E, Lenander C, Nilsson PJ, Rubio CA, Glimelius B. Tumour budding correlates with local recurrence of rectal cancer. Colorectal Dis. 2011;13:255–62.CrossRefPubMed
14.
Zurück zum Zitat van Wyk HC, Park JH, Edwards J, Horgan PG, McMillan DC, Going JJ. The relationship between tumour budding, the tumour microenvironment, and survival in patients with primary operable colorectal cancer. Br J Cancer 2016;115:156–63.CrossRefPubMedPubMedCentral van Wyk HC, Park JH, Edwards J, Horgan PG, McMillan DC, Going JJ. The relationship between tumour budding, the tumour microenvironment, and survival in patients with primary operable colorectal cancer. Br J Cancer 2016;115:156–63.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008;10:41–7.PubMed Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008;10:41–7.PubMed
16.
Zurück zum Zitat Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127:385–94.CrossRefPubMed Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127:385–94.CrossRefPubMed
17.
Zurück zum Zitat Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005;37:177–82.CrossRefPubMedPubMedCentral Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005;37:177–82.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005;48:1597–602.CrossRefPubMed Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005;48:1597–602.CrossRefPubMed
19.
Zurück zum Zitat Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 2008;51:568–72.CrossRefPubMed Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 2008;51:568–72.CrossRefPubMed
20.
Zurück zum Zitat Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Dis. 2014;16:259–64.CrossRefPubMed Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Dis. 2014;16:259–64.CrossRefPubMed
21.
Zurück zum Zitat Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19:3706–12.CrossRefPubMed Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19:3706–12.CrossRefPubMed
22.
Zurück zum Zitat Sy J, Fung CL, Dent OF, Chapuis PH, Bokey L, Chan C. Tumor budding and survival after potentially curative resection of node-positive colon cancer. Dis Colon Rectum 2010;53:301–7.CrossRefPubMed Sy J, Fung CL, Dent OF, Chapuis PH, Bokey L, Chan C. Tumor budding and survival after potentially curative resection of node-positive colon cancer. Dis Colon Rectum 2010;53:301–7.CrossRefPubMed
23.
Zurück zum Zitat Rieger G, Koelzer VH, Dawson HE, et al. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer. Histopathology 2017;70:1044–51.CrossRefPubMed Rieger G, Koelzer VH, Dawson HE, et al. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer. Histopathology 2017;70:1044–51.CrossRefPubMed
24.
Zurück zum Zitat Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44:697–705.CrossRefPubMed Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44:697–705.CrossRefPubMed
25.
Metadaten
Titel
Prognostic Impact of Tumor-Budding Grade in Stages 1–3 Colon Cancer: A Retrospective Cohort Study
verfasst von
Bo Young Oh, MD, PhD
Yoon Ah Park, MD
Jung Wook Huh, MD, PhD
Seong Hyeon Yun, MD, PhD
Hee Cheol Kim, MD, PhD
Ho-Kyung Chun, MD, PhD
Seok Hyung Kim, MD, PhD
Sang Yun Ha, MD, PhD
Woo Yong Lee, MD, PhD
Yong Beom Cho, MD, PhD
Publikationsdatum
30.10.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6135-5

Weitere Artikel der Ausgabe 1/2018

Annals of Surgical Oncology 1/2018 Zur Ausgabe

Health Services Research and Global Oncology

The Annals of Surgical Oncology: An Oncology Journal for Surgeons

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.